ZHU Jia-Zhen, YI Hong-Wei, HUANG Wei, PANG Tao, ZHOU Hui-Ping, WU Xu-Dong. Fatty liver diseases, mechanisms, and potential therapeutic plant medicines [J]. Chin J Nat Med, 2020, 18(3): 161-168. DOI: 10.1016/S1875-5364(20)30017-0
Citation: ZHU Jia-Zhen, YI Hong-Wei, HUANG Wei, PANG Tao, ZHOU Hui-Ping, WU Xu-Dong. Fatty liver diseases, mechanisms, and potential therapeutic plant medicines [J]. Chin J Nat Med, 2020, 18(3): 161-168. DOI: 10.1016/S1875-5364(20)30017-0

Fatty liver diseases, mechanisms, and potential therapeutic plant medicines

  • The liver is an important metabolic organ and controls lipid, glucose and energy metabolism. Dysruption of hepatic lipid metabolism is often associated with fatty liver diseases, including nonalcoholic fatty liver disease (NAFLD), alcoholic fatty liver diseases (AFLD) and hyperlipidemia. Recent studies have uncovered the contribution of hormones, transcription factors, and inflammatory cytokines to the pathogenesis of dyslipidemia and fatty liver diseases. Moreover, a significant amount of effort has been put to examine the mechanisms underlying the potential therapeutic effects of many natural plant products on fatty liver diseases and metabolic diseases. We review the current understanding of insulin, thyroid hormone and inflammatory cytokines in regulating hepatic lipid metabolism, focusing on several essential transcription regulators, such as Sirtuins (SIRTs), Forkhead box O (FoxO), Sterol-regulatory element-binding proteins (SREBPs). We also discuss a few representative natural products with promising thereapeutic effects on fatty liver disease and dyslipidemia.
  • loading

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return